IMNN · Imunon, Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-31 | Eylward Susan |
General Counsel and Corp Sec |
Sell↓
Filing footnotes — Common Stock (Direct)
Reflects a weighted average sale price of $1.5643 per share, at prices ranging from $1.55 to $1.58 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. |
Common Stock
|
2,525 |
| 2026-08-28 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
6,822 |
| 2026-08-28 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
3,626 |
| 2026-08-28 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
2,525 |
| 2026-08-28 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
7,371 |
| 2026-08-17 | Eylward Susan |
General Counsel and Corp Sec |
Sell↓
Filing footnotes — Common Stock (Direct)
Reflects a weighted average sale price of $1.6303 per share, at prices ranging from $1.61 to $1.655 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. |
Common Stock
|
2,449 |
| 2026-08-14 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
7,147 |
| 2026-08-14 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
3,516 |
| 2026-08-14 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
6,615 |
| 2026-08-14 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
2,449 |
| 2026-08-03 | Eylward Susan |
General Counsel and Corp Sec |
Sell↓
Filing footnotes — Common Stock (Direct)
Reflects a weighted average sale price of $1.5651 per share, at prices ranging from $1.56 to $1.575 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. |
Common Stock
|
2,541 |
| 2026-07-31 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
3,649 |
| 2026-07-31 | Dentzer James E |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
6,934 |
| 2026-07-31 | Braun Donald P |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
6,180 |
| 2026-07-31 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
5,010 |
| 2026-07-31 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
2,541 |
| 2026-07-31 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
6,358 |
| 2026-07-31 | Fritz Frederick J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees. |
Common Stock
|
6,934 |
| 2026-07-31 | Pellizzari Christine A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
6,934 |
| 2026-07-20 | Eylward Susan |
General Counsel and Corp Sec |
Sell↓
Filing footnotes — Common Stock (Direct)
Reflects a weighted average sale price of $1.7816 per share, at prices ranging from $1.76 to $1.79 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. |
Common Stock
|
2,150 |
| 2026-07-17 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
3,082 |
| 2026-07-17 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
2,150 |
| 2026-07-17 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
4,907 |
| 2026-07-17 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
4,603 |
| 2026-07-06 | Eylward Susan |
General Counsel and Corp Sec |
Sell↓
|
Common Stock
|
920 |
| 2026-07-02 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
920 |
| 2026-07-02 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
4,410 |
| 2026-07-02 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
2,534 |
| 2026-07-02 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
1,308 |
| 2026-06-29 | Eylward Susan |
General Counsel and Corp Sec |
Sell↓
Filing footnotes — Common Stock (Direct)
Reflects a weighted average sale price of $1.752 per share, at prices ranging from $1.73 to $1.80 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. |
Common Stock
|
11,800 |
| 2026-06-25 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for 50% of 2025 annual cash bonus |
Common Stock
|
42,519 |
| 2026-06-25 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for 50% of 2025 annual cash bonus |
Common Stock
|
14,696 |
| 2026-06-25 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for 50% of 2025 annual cash bonus |
Common Stock
|
21,896 |
| 2026-06-25 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for 50% of 2025 annual cash bonus |
Common Stock
|
67,150 |
| 2026-06-18 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
1,803 |
| 2026-06-18 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
4,629 |
| 2026-06-05 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
4,089 |
| 2026-06-05 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
1,593 |
| 2026-05-22 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
1,491 |
| 2026-05-22 | Pellizzari Christine A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
5,557 |
| 2026-05-22 | Braun Donald P |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
5,011 |
| 2026-05-22 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
3,484 |
| 2026-05-22 | Fritz Frederick J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees. |
Common Stock
|
10,330 |
| 2026-05-22 | Dentzer James E |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
11,148 |
| 2026-01-02 | Fritz Frederick J. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
5,892 |
| 2026-01-02 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
43,821 |
| 2026-01-02 | Bragg Kimberly |
CFO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
9,050 |
| 2026-01-02 | Braun Donald P |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
5,881 |
| 2026-01-02 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
12,667 |
| 2026-01-02 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
56,187 |